Dr. Pol F. Boudes M.D., Ph.D. is the Chief Medical Officer at Galectin Therapeutics Inc.
As the Chief Medical Officer of Galectin Therapeutics Inc, the total compensation of Dr D at Galectin Therapeutics Inc is $688,557. There are 2 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
Dr D is 64, he's been the Chief Medical Officer of Galectin Therapeutics Inc since . There are 7 older and 11 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
Pol's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE240, NORCROSS, GA, 30071.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr und Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: